BioSpace News Archive

NeuroRx, Inc. reports 60-day results of the Phase 2b/3 trial of intravenously-administered ZYESAMI™ for the treatment of respiratory failure in critically-ill patients with COVID-19, which is being developed in collaboration with Relief Therapeutics Holding AG.

Tiziana Life Sciences., a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces that the Chairman and founder, Gabriele Cerrone, will give an interview on Bloomberg Television on Monday, 29 March 2021 at 1.20 p.m. US Eastern Standard Time as part of the Bloomberg Surveillance Show.

Masimo announced the results of a prospective, observational study published in Acta Paediatrica in which researchers from the Hospital for Sick Children in Toronto evaluated the accuracy of plethysmographic respiration rate measurement using Masimo Rad-G™, a rugged, handheld device, on malnourished, hospitalized children in Nigeria.1

QIAGEN N.V. announced the Emergency Use Authorization by the U.S. FDA for the NeuMoDx™ Flu A-B/RSV/SARS-CoV-2 Vantage Assay that will help healthcare professionals quickly identify and differentiate individuals suspected by a healthcare provider of respiratory viral infection consistent with COVID-19.

Hemogenyx Pharmaceuticals plc announces that it has allotted 1,000,000 new ordinary shares of £0.01 each in the Company in consideration for finance consulting services to Prosdocimi Limited.

Up to 400 million doses of the Company’s single-shot vaccine candidate will be made available to African Union member states

Genestack Ltd. announced that its flagship multi-omics data catalog, curation and integrative search product, Omics Data Manager, has been licensed and implemented by the Dutch vegetable breeding firm Bejo.

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has entered into a licensing agreement with Simcere Pharmaceutical Group Ltd (Simcere) (HKSE: 2096) to develop and commercialise Kazia’s investigational new drug, paxalisib, in Greater China.

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, announced that management will host a conference call and webcast today at 8am ET to discuss topline results from the Phase 3 clinical trial of lenzilumab in patients hospitalized with COVID-19.

Xilio Therapeutics, a biotechnology company developing potent, tumor-selective immuno-oncology therapies for people living with cancer, today announced the appointments of Salvatore Giovine as chief financial officer (CFO) and Chris Frankenfield as general counsel, effective March 29, 2021.